Recent advances in the development of Rho kinase inhibitors (2015–2021)
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/06/02
-
Journal
-
Indian UGC (journal)
-
Refrences112
-
Citations1
-
Xiangrong Xu Yantai University Hospital Yantai University Yantai China ORCID (unauthenticated)
-
Lei Yao School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai China ORCID (unauthenticated)
Abstract
Cite
Xu, Xiangrong, and Lei Yao. “Recent Advances in the Development of Rho Kinase Inhibitors (2015–2021)”. Medicinal Research Reviews, vol. 44, no. 1, 2023, pp. 406-21, https://doi.org/10.1002/med.21980.
Xu, X., & Yao, L. (2023). Recent advances in the development of Rho kinase inhibitors (2015–2021). Medicinal Research Reviews, 44(1), 406-421. https://doi.org/10.1002/med.21980
Xu, Xiangrong, and Lei Yao. “Recent Advances in the Development of Rho Kinase Inhibitors (2015–2021)”. Medicinal Research Reviews 44, no. 1 (2023): 406-21. https://doi.org/10.1002/med.21980.
Xu X, Yao L. Recent advances in the development of Rho kinase inhibitors (2015–2021). Medicinal Research Reviews. 2023;44(1):406-21.
Journal Categories
Medicine
Public aspects of medicine
Toxicology
Poisons
Medicine
Therapeutics
Pharmacology
You May Also Like
- Carbonic anhydrase inhibitors and their therapeutic potential
- Antiglaucoma carbonic anhydrase inhibitors: a patent review
- Applications of carbonic anhydrase inhibitors and activators in therapy
- Toxic Metals and Oxidative Stress Part I: Mechanisms Involved in Me-tal induced Oxidative Damage
- Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| The design, synthesis and evaluation of Rho‐kinase inhibitory activity of 4‐aryl‐thiazole‐2‐amines | Iranian Journal of Pharmaceutical Research |
| 2021 | |
| Effects of the Rho‐kinase inhibitor fasudil on the invasion, migration, and apoptosis of human prostate cancer PC3 and DU145 cells | 2016 | |||
| The application of Rho‐associated protein kinase (ROCK) inhibitors in neurodegenerative diseases | 2016 | |||
| A straightforward and efficiently scaleable synthesis of novel racemic 4‐substituted‐2,8‐diazaspiro[4.5]decan‐1‐one derivatives | Synthesis |
| 2015 | |
ROCK inhibitors for the treatment of ocular diseases | British Journal of Ophthalmology |
| 19 | 2017 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target | International Journal of Molecular Sciences |
| 2023 |
Citations Analysis
| Category | Category Repetition |
|---|---|
| Science: Biology (General) | 1 |
| Science: Chemistry: General. Including alchemy | 1 |
| Science: Chemistry | 1 |
The category
Science: Biology (General) 1
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target and was published in 2023. The most recent citation comes from a 2023 study titled Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target. This article reached its peak citation in 2023, with 1 citations. It has been cited in 1 different journals. Among related journals, the International Journal of Molecular Sciences cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.